Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below Two Hundred Day Moving Average – What’s Next?

Shares of Akari Therapeutics, Plc (NASDAQ:AKTX) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.46 and traded as low as $1.10. Akari Therapeutics shares last traded at $1.20, with a volume of 17,294 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a research note on Saturday. They issued a “sell” rating for the company.

Akari Therapeutics Stock Performance

The company’s 50-day moving average price is $1.11 and its 200-day moving average price is $1.45.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.